Last reviewed · How we verify
CHLORTHALIDONE
At a glance
| Generic name | CHLORTHALIDONE |
|---|---|
| Also known as | chlortalidone |
| Drug class | Thiazide-like Diuretic [EPC] |
| Target | Na+/Cl− cotransporter |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Hypertension — 1L
- Edema associated with congestive heart failure — adjuvant
- Edema associated with hepatic cirrhosis — adjuvant
- Edema due to corticosteroid and estrogen therapy — adjuvant
- Edema due to renal dysfunction — adjuvant
Pipeline indications
- Cardiac effects of mineralocorticoid receptor antagonism after preeclampsia — Phase 2
- Indapamide and chlorthalidone to reduce urine supersaturation for kidney stone prevention — Phase 2
- Spironolactone in CKD enabled by chlorthalidone — Phase 2
- Safety and efficacy of chlorthalidone in type 1 diabetes — Phase 2
- Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension — Phase 3
Common side effects
- Anorexia
- Gastric irritation
- Nausea
- Vomiting
- Cramping
- Diarrhea
- Constipation
- Jaundice
- Pancreatitis
- Dizziness
- Vertigo
- Paresthesias
Drug interactions
- Other antihypertensive drugs
- Digitalis
- Insulin
- Oral hypoglycemics
- Tubocurarine
- Norepinephrine
Key clinical trials
- OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) (NA)
- Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension. (EARLY_PHASE1)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
- Hypertension in Young Adults Trial (PHASE2)
- Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension (PHASE4)
- Diuretics and Volume Overload in Early CKD (PHASE4)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHLORTHALIDONE CI brief — competitive landscape report
- CHLORTHALIDONE updates RSS · CI watch RSS